<DOC>
	<DOCNO>NCT02096068</DOCNO>
	<brief_summary>The drug Dexmedetomidine investigate 72 patient ( men woman ) undergo elective cardiac abdominal surgery . The study medication administer perioperatively intravenous infusion continuously ( long 48 h ) prevent/reduce rate Delirium incidence postoperative cognitive deficit ( POCD ) . A non-surgical control group 15 ASA II/III- patient Berlin surround area collect measure learn experience cognitive testing . The participant match age , education , gender study patient . Cognitive testing perform patient study group ( n= 72 ) control group ( n= 15 ) evaluate deficit cognitive area ( POCD ( Postoperative cognitive deficit ) ) three different time point three month .</brief_summary>
	<brief_title>Neuroprotection With Dexmedetomidine Patients Undergoing Elective Cardiac Abdominal Surgery ( Neuprodex )</brief_title>
	<detailed_description />
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Study Group : 1 . Patients age ≥ 60 year 2 . Male female patient undergo elective cardiac ( elective CABGsurgery without valve surgery leave ventricular ejection fraction ≥ 30 % ) pancreatic hepatic gastric intestinal surgery Campus Charité Mitte Campus Virchow Klinikum , Charité Universitätsmedizin Berlin 3 . Offered patient information write consent patient ( accord German Drug Law § 40 ( 1 ) 3b ) 4 . Premedication benzodiazepines 5 . Pain therapy operation regional procedure and/or Sufentanil/Fentanyl 6 . Anesthesia cardio surgery accord HeartLungApparatus 7 . Anesthesia hypnotic agent Propofol 8 . Pain therapy operation accord S3Guideline 9 . Postoperative medication anxiolysis benzodiazepines 1 . Known drug intolerance/allergy : dexmedetomidine ingredient 2 . Lacking willingness save hand pseudonymised data within clinical trial 3 . Accommodation institution due official judicial order ( accord AMG §40 ( 1 ) 4 ) 4 . Employee Charité Universitätsmedizin Berlin CVK/CCM 5 . Illiteracy 6 . Inability speak and/or read German 7 . Minimal mental status examination ( MMSE ) &lt; 24 8 . Severe hearing loss visual impairment 9 . Acute brain injury 10 . Intracranial haemorrhage within one year participation study 11 . Manifest psychiatric disease 12 . Known illicit substance abuse 13 . Acute intoxication 14 . For woman : Pregnancy positive pregnancy test within preoperative screen 15 . Homeless circumstance , patient would reachable telephone postal service 3months follow 16 . Participation another interventional clinical trial accord German Drug Law time inclusion trial 17 . Acute circulatory failure time randomisation ( severe hypotension mean arterial pressure &lt; 55 mmHg despite vasopressor optimal preload ) 18 . AVconductionblock II III ( unless pacemaker instal ) 19 . Severe bradycardia ( heartrate &lt; 50 bpm , preoperative , permanent ) 20 . Spinal cord injury know autonomic dysregulation 21 . Preoperative acute cerebrovascular event neurologic residues 22 . Liver insufficiency ( Child C cirrhosis , MELD Score &gt; 17 ) 23 . Application Remifentanil operation 24 . Deep sedation ( RASS , 4 5 ) 25 . Administration Clonidine administration study drug 26 . Additional administration Dexmedetomidine within 3 month study inclusion Control Group : 1 . Patients age ≥ 60 year European descent ( Caucasian ) 2 . Male female patient ASA II+III 3 . ASA II+IIIpatients , operation plan within next year 4 . No operation last half year study inclusion 5 . Offered patient information write informed consent Exclusion Criteria 1 . Minimal mental status examination ( MMSE ) &lt; 24 2 . Missing informed consent save hand pseudonymous data 3 . Neuropsychiatric morbidity , limit conduction neurocognitive test 4 . Anacusis Hypoacusis , limit conduction neurocognitive test 5 . Taking psychothropic drug ( include sleepinducing drug benzodiazepine ) regular basis substance , limit conduction neurocognitive testing</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuroprotection</keyword>
</DOC>